Clearwater Analytics (CWAN) - 2024 Q4 - Annual Report

Financial Performance - Total revenue for 2024 reached $451.8 million, a 22.7$368.2 million in 2023[360]. - Gross profit for 2024 was $328.8 million, up 25.9$261.0 million in 2023[360]. - Net income for 2024 was $427.6 million, compared to a net loss of$23.1 million in 2023[360]. - Comprehensive income for 2024 was $423.1 million, compared to a loss of$20.3 million in 2023[362]. - Basic net earnings per share for 2024 were $1.93, a recovery from a loss of$0.11 per share in 2023[360]. - Employee compensation expense increased to $208.4 million in 2024, up from$184.7 million in 2023, reflecting a 12.7% rise[492]. - Consolidated net income for 2024 was $427.6 million, a significant recovery from a net loss of$23.1 million in 2023[492]. Assets and Liabilities - As of December 31, 2024, the total assets loaded on the platform reached $8.8 trillion, up from$7.3 trillion in 2023, indicating a significant growth in asset management[19]. - Total assets as of December 31, 2024, were $1.17 billion, significantly up from$558.7 million in 2023[358]. - The company reported a debt balance of $46.1 million under the Credit Agreement, with a potential interest expense fluctuation of approximately$0.2 million for a hypothetical 100 basis points change in the Secured Overnight Financing Rate (SOFR)[332]. - The company’s net carrying amount of debt as of December 31, 2024, was $45.914 million, with future maturities of$2.750 million due in 2025 and $43.313 million in 2026[460]. - Total stockholders' equity attributable to Clearwater Analytics Holdings, Inc. increased to$1.01 billion in 2024, compared to $354.3 million in 2023[358]. Tax and Deferred Assets - Deferred tax assets related to the investment in partnership amounted to$514 million as of December 31, 2024, reflecting the company's strategic financial positioning[344]. - The company reported a total of $625.1 million in deferred tax assets as of December 31, 2024, compared to$512.9 million in 2023[499]. - The valuation allowance decreased by $493 million during 2024, primarily due to the release of the valuation allowance on most U.S. federal and state deferred tax assets[501]. - The effective tax rate for 2024 was 1,522.3$7.329 million in 2024 from $2.766 million in 2023, marking a growth of about 164.5$2.4 million of total revenue was included in the deferred revenue balance as of December 31, 2023, related to the company's SaaS solution[439]. Acquisitions and Growth - The company completed the acquisition of Wilshire Technology for a total purchase consideration of $40.1 million in cash on April 22, 2024, which includes goodwill of$28.24 million attributed to expected post-acquisition synergies[443][445]. - The company entered into a merger agreement to acquire Enfusion, Inc. for approximately $1.5 billion, expected to close in Q2 2025, subject to shareholder and regulatory approvals[517][518]. - A senior secured term loan B facility of$800 million was completed to finance part of the cash consideration for the Enfusion acquisition, with an interest rate based on SOFR plus 2.25%[519]. Operational Challenges - The company faces prolonged sales cycles and substantial upfront sales costs when targeting large financial institutions, which may affect revenue predictability[16]. - The company relies heavily on fees based on the value of assets on its platform, making it vulnerable to market volatility and economic downturns[16]. - Rising inflation has impacted operations in India, although it has not materially affected the overall business performance as of now[333]. Internal Controls and Audit Matters - The company maintains effective internal control over financial reporting as of December 31, 2024, according to the independent auditor's opinion[351]. - The evaluation of deferred tax assets is considered a critical audit matter, requiring complex judgment and specialized knowledge[345]. Stock and Equity - The company issued 291,266 shares under the Employee Stock Purchase Plan (ESPP), generating $4,693,000 in additional capital[365]. - The total paid-in capital increased to$725,174,000 as of December 31, 2024, up from $532,507,000 in 2023[365]. - The total number of shares outstanding as of December 31, 2023, was 212,857,580, reflecting significant growth from the previous year[365]. - The Company granted 4.1 million RSUs in 2024, with a weighted average grant date fair value of$20.02[477]. Research and Development - Research and development expenses increased to $150.6 million in 2024, a 21.5$123.9 million in 2023[360]. - Research and development costs consist of personnel expenses, including salaries and benefits, for employees engaged in the design and development of the Company's offerings[415].